News

High Monocyte Levels Linked to Poorer Outcomes in IPF, and Other Fibrotic Diseases, Study Finds

Apr 09, 2019

Blood levels of immune cells called monocytes may help predict disease severity and determine the risk of poor outcomes in patients with idiopathic pulmonary fibrosis and other fibrotic diseases, a retrospective study suggests.

Secondary Insurance Coverage Boosts Adherence to Treatment with Ofev, Esbriet, Study Finds

Apr 08, 2019

Although patients with idiopathic pulmonary fibrosis who take the anti-fibrotic medications Ofev or Esbriet have similar clinical outcomes, adherence to treatment is higher among those who have secondary insurance coverage, especially from charitable organizations, a study finds.

IPF Patients’ Quality of Life Linked to Lung Changes, Comorbidities, Disease’s Course

Apr 02, 2019

The quality of life of people with idiopathic pulmonary fibrosis (IPF) is strongly associated with clinical changes in lung function, comorbidities, disease duration, and overall clinical course of the disease, a study shows.

PRM-151 Receives FDA Breakthrough Therapy Designation for IPF Treatment

Mar 27, 2019

The U.S. Food and Drug Administration has granted breakthrough therapy designation to PRM-151, a compound being investigated for the treatment of idiopathic pulmonary fibrosis (IPF).

Study Finds Increased Risk of PF Among World Trade Center Responders

Mar 19, 2019

Exposure to dust in the aftermath of the World Trade Center attacks increased the risk of pulmonary fibrosis (PF) among responders, according to an evaluation of self-reported surveys. Researchers found that higher levels of dust exposure were associated with increased PF incidence.